IDYA Stock Analysis: Ideaya Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.547m USD | 12M Return: 56.7% | US45166A1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.6M
Qual. Beats: 0
Rev. Trend: 63.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ideaya Biosciences (IDYA) is a US-based clinical-stage precision medicine oncology company that develops targeted therapeutics for genetically defined patient populations, using molecular diagnostics to select those most likely to benefit from treatment. The companys lead clinical asset, Darovasertib, is an oral protein kinase C (PKC) inhibitor being developed primarily for uveal melanoma, with additional evaluations in ocular cancers and in combination with crizotinib across metastatic, neoadjuvant, and adjuvant settings.
IDYAs broader pipeline includes multiple early- and mid-stage oncology programs targeting high-interest oncology vulnerabilities such as MAT2A inhibition in MTAP-deleted tumors (IDE397), PRMT5 inhibition (IDE892), poly ADP-ribose glycohydrolase (PARG) inhibition (IDE161), and a DLL3 antibody-drug conjugate (IDE849) for small cell lung cancer. The company is also advancing a bispecific topoisomerase-I payload B7H3/PTK7 ADC (IDE034), a Werner helicase (WRN) inhibitor (IDE275), a KAT6/7 inhibitor (IDE574), and a Pol theta helicase inhibitor (IDE705/GSK101) in collaboration with GlaxoSmithKline. Its discovery engine is built on the DECIPHER dual CRISPR library for synthetic lethality target identification, the INQUIRE chemical library, and the HARMONY machine-learning platform for compound optimization.
As a mid-cap clinical-stage biotechnology company, IDYA has historically depended on a partnership-driven business model, with strategic alliances and clinical collaborations with major pharmaceutical companies including GlaxoSmithKline, Pfizer, Gilead Sciences, Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals, and Les Laboratoires Servier. Additional active clinical collaborations include agreements with AstraZeneca to evaluate IDE849 and with Roche to evaluate IDE892 in combination with Roches pan-PI3Kα inhibitor RG6505, supporting IDYAs approach of leveraging external pharma expertise to advance its precision oncology pipeline.
- Darovasertib Phase 3 data in uveal melanoma could unlock first approval
- GSK and Pfizer partnership milestones extend cash runway
- MAT2A and PRMT5 programs face rising competitive pressure
| Net Income: -175.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 14.04 > 1.0 |
| NWC/Revenue: 333.7% < 20% (prev 9.00k%; Δ -8.67k% < -1%) |
| CFO/TA -0.14 > 3% & CFO -186.8m > Net Income -175.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.1m) vs 12m ago 4.06% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 19.92% > 50% (prev 0.67%; Δ 19.25% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.60 (Total Current Assets 864.0m - Total Current Liabilities 82.7m) / Total Assets 1.31b |
| B: -0.72 (Retained Earnings -947.5m / Total Assets 1.31b) |
| C: -0.18 (EBIT TTM -217.0m / Avg Total Assets 1.18b) |
| D: 10.82 (Book Value of Equity 1.20b / Total Liabilities 110.8m) |
| Altman-Z'' = 11.68 = AAA |
As of August 13, 2026, the stock is trading at USD 36.96 with a total of 473,054 shares traded. Over the past week, the price has changed by +2.55%, over one month by +2.24%, over three months by +31.44% and over the past year by +56.68%.
Current recommended Stop Loss: 33.50 (which is 9.4% or 2.5 ATR below the current price).
Ideaya Biosciences has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy IDYA.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52.2 | 41.1% |
P/E Forward = 4.649
P/S = 15.1489
P/B = 2.9535
Revenue TTM = 234.1m USD
EBIT TTM = -217.0m USD
EBITDA TTM = -212.5m USD
Long Term Debt = 28.1m USD (estimated: total debt 29.3m - short term 1.19m)
Short Term Debt = 1.19m USD (from shortTermDebt, last quarter)
Debt = 29.3m USD (from shortLongTermDebtTotal, last quarter) (leases 29.3m already included)
Net Debt = -799.6m USD (calculated: Debt 29.3m - CCE 829.0m)
Enterprise Value = 2.75b USD (3.55b + Debt 29.3m - CCE 829.0m)
Interest Coverage Ratio = unknown (Ebit TTM -217.0m / Interest Expense TTM 0.0)
EV/FCF = -14.46x (Enterprise Value 2.75b / FCF TTM -190.0m)
FCF Yield = -6.92% (FCF TTM -190.0m / Enterprise Value 2.75b)
FCF Margin = -81.16% (FCF TTM -190.0m / Revenue TTM 234.1m)
Net Margin = -74.75% (Net Income TTM -175.0m / Revenue TTM 234.1m)
Gross Margin = unknown ((Revenue TTM 234.1m - Cost of Revenue TTM 4.59m) / Revenue TTM)
Tobins Q-Ratio = 2.10 (Enterprise Value 2.75b / Total Assets 1.31b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 29.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -171.4m (EBIT -217.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.45 (Total Current Assets 864.0m / Total Current Liabilities 82.7m)
Debt / Equity = 0.02 (Debt 29.3m / totalStockholderEquity, last quarter 1.20b)
Debt / EBITDA = 3.76 (negative EBITDA) (Net Debt -799.6m / EBITDA -212.5m)
Debt / FCF = 4.21 (negative FCF - burning cash) (Net Debt -799.6m / FCF TTM -190.0m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.89% (Net Income -175.0m / Total Assets 1.31b)
RoE = -16.47% (Net Income TTM -175.0m / Total Stockholder Equity 1.06b)
RoCE = -19.89% (EBIT -217.0m / Capital Employed (Equity 1.06b + L.T.Debt 28.1m))
RoIC = -14.09% (negative operating profit) (NOPAT -171.4m / Invested Capital 1.22b)
WACC = 8.16% (E(3.55b)/V(3.58b) * Re(8.23%) + D(29.3m)/V(3.58b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.21 | Cagr: 9.47%
[DCF] Fair Price = unknown (Cash Flow -190.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.05 | # QB: 0
Revenue Correlation: 63.53 | Revenue CAGR: 207.8% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.17 | Chg30d=-11.89% | Revisions=+40% | Analysts=13
EPS current Year (2026-12-31): EPS=-4.61 | Chg30d=-7.65% | Revisions=+40% | GrowthEPS=-260.2% | GrowthRev=-82.0%
EPS next Year (2027-12-31): EPS=-4.11 | Chg30d=-12.44% | Revisions=+40% | GrowthEPS=+10.9% | GrowthRev=+193.5%
[Analyst] Revisions Ratio: +67% (up=6, down=0)